Recent definitions for clinical utility of molecular tests focus on whether a test result will alter treatment. This definition neglects other uses of molecular testing to diagnose disease, manage symptoms, prognosticate or predict future disease. The fullest realization of precision medicine will require embracing all aspects of clinical utility. This three-part webinar series, supported by AMP, presents the discussions of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility (FEND) working group, and its resulting publication, “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology” (Joseph L, et al. J Mol Diagn. 2016;18:605–619).
Part 1 - An Overview of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility
Speakers: Loren Joseph, MD; Elaine Lyon, PhD
Host: Roger Klein, MD, JD
Part 2 - AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Oncology Cases
Speakers: Pranil Chandra, DO, FCAP, FASP; Rajyasree Emmadi, MD, FCAP
Host: Loren Joseph, MD
Part 3: AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Inherited Conditions
Speakers: Stephanie Hallam, PhD, FACMG, MBA; Victoria Pratt, PhD, FACMG
Host: Elaine Lyon, PhD
Total Duration: 3 hr
All sales are final. No refunds will be issued.
Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
September 28, 2016
AMP Regular Member: $0.00
AMP Technologist Member: $0.00
AMP Associate Member: $0.00
Non-member Price: $526.50
Purchase Individual Topics